← All trials
NCT05741528
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2023
- Primary completion
- Jan 10, 2025
- Completion date
- Jan 10, 2025
- First posted
- Feb 23, 2023
- Last posted
- Jun 29, 2023
- Enrollment
- 67
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sumitomo DainipponLead sponsor
- Sumitomo DainipponStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.